Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Join SI Premium – FREE
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $0 , versus $30 thousand reported last year.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
- BWS Financial Downgrades Inter Parfums (IPAR) to Sell
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
